当前位置: 首页 >> 检索结果
181. Intracranial giant cell arteritis: a comprehensive systematic review.
作者: Sagar Patel.;Iva Okaj.;Jessica Scott.;Sukhreet Atwal.;Colin Stark.;Rabia Tahir.;Nader Khalidi.;Mats Junek.
来源: Rheumatology (Oxford). 2025年
Giant cell arteritis (GCA) is increasingly recognized to occur in intracranial vessels with unknown clinical ramifications. We identified all reported cases of intracranial GCA (ICGCA) in the literature to describe common presentations, investigations, treatments, and outcomes.
182. "As long as you learn to adapt"-a longitudinal mixed-methods study exploring the first decade with rheumatoid arthritis.
作者: Maria Bergström.;Åsa Larsson Ranada.;Annette Sverker.;Ingrid Thyberg.;Mathilda Björk.
来源: BMC Rheumatol. 2025年9卷1期35页
Early diagnosis and modern treatment have changed everyday life of patients with rheumatoid arthritis (RA). However, symptoms are still pronounced several years after diagnosis. The aim of this study is therefore to synthesise the perception of everyday life in men and women with contemporary treated RA over the course of the first decade after diagnosis. This will be achieved by comparing subjective experiences with quantitative measures of disability and disease activity.
184. Systemic autoinflammatory disease diagnoses in a single year from a UK national referral centre.
作者: Hugh Caterson.;Charalampia Papadopoulou.;Claire Peet.;Helen J Lachmann.
来源: Rheumatology (Oxford). 2025年
The diagnosis of systemic autoinflammatory diseases (SAIDs) is frequently missed or delayed. The establishment of specialist clinics and availability of genetic testing enables increased diagnosis of these disorders. We aimed to study the case mix and demographics of patients referred to a UK national centre for primarily adult SAID.
185. Exploring the relationship between skin severity and PASDAS in psoriatic arthritis: a cross-sectional study in the BSR-PsA and GRACE cohorts.
作者: Michelle L M Mulder.;Gareth T Jones.;Ovidiu Rotariu.;Philip S Helliwell.
来源: Rheumatology (Oxford). 2025年
To explore the extent to which skin severity is reflected in the Psoriatic arthritis Disease Activity Score (PASDAS).
186. Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study.
作者: Masaki Hatano.;Akira Okada.;Yusuke Sasabuchi.;Hisatoshi Ishikura.;Takeyuki Tanaka.;Taku Saito.;Sakae Tanaka.;Hideo Yasunaga.
来源: Rheumatology (Oxford). 2025年
To compare the incidence of gout in individuals with diabetes receiving metformin vs sodium-glucose co-transporter-2 inhibitors (SGLT-2is).
188. Immunosuppressant withdrawal versus glucocorticoid withdrawal in systemic lupus erythematosus: 2-year outcomes of a noninferiority randomized controlled trial.
作者: Aishwarya Gopal.;Chengappa Kavadichanda.;Christina Mary Mariaselvam.;K T Harichandrakumar.;Molly Mary Thabah.;Vir Singh Negi.
来源: Rheumatology (Oxford). 2025年
This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with Systemic Lupus Erythematosus (SLE) in remission.
189. Association between cardiovascular risk factors and the occurrence of giant cell arteritis: a systematic review and meta-analysis.
作者: François Barde.;Lucas Pacoureau.;Alexis Elbaz.;Raphaèle Seror.;Yann Nguyen.
来源: Rheumatology (Oxford). 2025年
We aimed to analyze the association between cardiovascular risks factors and the onset of giant cell arteritis (GCA) through a systematic review and meta-analysis of observational studies.
192. The status and correlation factors of fatigue in patients with ankylosing spondylitis (FACIT-F): a cross-sectional study based on the Chinese population.
作者: Tiantian Sun.;Kun Yang.;Yuening Chen.;Zhaoyang Geng.;Xinning Qu.;Qing Yu.;Hongxiao Liu.
来源: BMC Rheumatol. 2025年9卷1期34页
To analyze the status and correlation factors of fatigue in patients with ankylosing spondylitis (AS), and provide a reference for improving the fatigue status of patients with AS.
193. Improving polymyalgia rheumatica care: considerations for routine vascular ultrasound in clinical practice.
作者: Max Yates.;Charlotte Davies.;Alexander James MacGregor.
来源: Lancet Rheumatol. 2025年7卷6期e448-e450页
Vascular ultrasound can be useful in the diagnostic investigation of patients with suspected giant cell arteritis. The clinical overlap between polymyalgia rheumatica and giant cell arteritis raises the prospect that vascular ultrasound can be used to identify features suggestive of giant cell arteritis in polymyalgia rheumatica, and has generated debate on whether all patients with polymyalgia rheumatica should undergo vascular ultrasound. However, before this approach becomes routine practice, more careful and detailed scrutiny is needed of its clinical necessity, patient benefit, and cost-effectiveness, where data are currently lacking. We argue that the case for universal vascular ultrasound screening in polymyalgia rheumatica is speculative and there is a greater necessity to direct resources to address misdiagnosis and overtreatment with glucocorticoids, which carry risks such as osteoporosis, diabetes, ocular morbidity, and infection.
195. Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER Cohort.
作者: Kohei Tsujimoto.;Kosuke Ebina.;Satomi Okamura.;Yasutaka Okita.;Yuki Etani.;Wataru Yamamoto.;Akira Onishi.;Hideo Onizawa.;Iku Shirasugi.;Naoki Nakano.;Takuya Kotani.;Yuri Hiramatsu.;Motomu Hashimoto.;Tadashi Okano.;Yuji Nozaki.;Chisato Ashida.;Yonsu Son.;Akihiro Tanaka.;Ryota Hara.;Seiji Okada.;Atsushi Kumanogoh.
来源: Rheumatology (Oxford). 2025年
This multicentre retrospective study aimed to evaluate differences in drug continuation rates and efficacy between first- and second-line use of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi) after failure of the initial therapy in real-world rheumatoid arthritis (RA) settings.
196. How have the clinical, laboratory, treatment features, and outcomes in children with lupus nephritis progressed over the last 30 years?
作者: Deniz Gezgin Yıldırım.;Nihal Karaçayır.;Hakan Kısaoğlu.;Aydan Yekedüz Bülbül.;Pınar Garipçin.;Hülya Nalçacıoğlu.;Mukaddes Kalyoncu.;Hakan Poyrazoğlu.;Sevcan A Bakkaloğlu.
来源: Rheumatology (Oxford). 2025年
Management of systemic lupus erythematosus (SLE) through new treatment options has improved lupus nephritis (LN) prognosis. The aim of this study was to compare the changes in the demographic, laboratory, and treatment characteristics, prognosis, and outcomes of pediatric-onset LN patients over 30 years.
198. Executive Summary: The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis.
作者: Lara S Chapman.;Michael Backhouse.;Nadia Corp.;Danielle van der Windt.;Lindsay Bearne.;Lindsey Cherry.;Gavin Cleary.;Jasmine Davey.;Rachel Ferguson.;Philip Helliwell.;Adam Lomax.;Helen McKeeman.;Alan A Rawlings.;Robin Rees.;Robbie Rooney.;Sarah Ryan.;Lucy Sanders.;Heidi J Siddle.;Sue Varley.;Louise Warburton.;Jim Woodburn.;Edward Roddy.; .
来源: Rheumatology (Oxford). 2025年64卷5期2347-2354页 199. The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis.
作者: Lara S Chapman.;Michael Backhouse.;Nadia Corp.;Danielle van der Windt.;Lindsay Bearne.;Lindsey Cherry.;Gavin Cleary.;Jasmine Davey.;Rachel Ferguson.;Philip Helliwell.;Adam Lomax.;Helen McKeeman.;Alan A Rawlings.;Robin Rees.;Robbie Rooney.;Sarah Ryan.;Lucy Sanders.;Heidi J Siddle.;Sue Varley.;Louise Warburton.;Jim Woodburn.;Edward Roddy.; .
来源: Rheumatology (Oxford). 2025年64卷5期2355-2368页 200. Genetically-determined variation in C-reactive protein impacts disease activity assessment in rheumatoid arthritis.
作者: Thomas R Riley.;Austin M Wheeler.;Grant W Cannon.;Brian Sauer.;Katherine D Wysham.;Bryant R England.;Kristin Wipfler.;Kaleb Michaud.;Michael March.;Scott M Damrauer.;Anurag Verma.;Michael D George.;Ted R Mikuls.;Joshua F Baker.
来源: Rheumatology (Oxford). 2025年
In patients with rheumatoid arthritis, we evaluated a single-nucleotide variant previously associated with lower C-reactive protein (CRP) to assess if this impacts clinical disease activity assessments including the disease activity score-28 with CRP (DAS28(CRP)).
|